Esperion Therapeutics Inc banner

Esperion Therapeutics Inc
NASDAQ:ESPR

Watchlist Manager
Esperion Therapeutics Inc Logo
Esperion Therapeutics Inc
NASDAQ:ESPR
Watchlist
Price: 3.13 USD Market Closed
Market Cap: $803.8m

Wall St Price Targets

ESPR Price Targets Summary
Esperion Therapeutics Inc

Wall Street analysts forecast ESPR stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ESPR is 2.97 USD with a low forecast of 1.8 USD and a high forecast of 3.44 USD.

Lowest Forecast
Price Target
1.8 USD
43% Downside
Average Forecast
Price Target
2.97 USD
5% Downside
Highest Forecast
Price Target
3.44 USD
10% Upside
Esperion Therapeutics Inc Competitors:
Price Targets
GTES
Gates Industrial Corporation PLC
32% Upside
FCNCA
First Citizens BancShares Inc (Delaware)
14% Upside

Revenue
Forecast

N/A
Past Growth
3% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
N/A
Past Growth
3% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

The compound annual growth rate for Revenue over the next 8 years is 3%.

Operating Income
Forecast

N/A
Past Growth
28% / Year
Estimated Growth
Estimates Accuracy
-4%
Average Miss
N/A
Past Growth
28% / Year
Estimated Growth
Estimates Accuracy
-4%
Average Miss

The compound annual growth rate for Operating Income over the next 8 years is 28%.

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-90%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-90%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is ESPR's stock price target?
Price Target
2.97 USD

According to Wall Street analysts, the average 1-year price target for ESPR is 2.97 USD with a low forecast of 1.8 USD and a high forecast of 3.44 USD.

What is the Revenue forecast for Esperion Therapeutics Inc?
Projected CAGR
3%

The compound annual growth rate for Revenue over the next 8 years is 3%.

What is the Operating Income forecast for Esperion Therapeutics Inc?
Projected CAGR
28%

The compound annual growth rate for Operating Income over the next 8 years is 28%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett